share_log

Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37

Benzinga ·  Mar 2 01:14

Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and raises the price target from $33 to $37.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment